An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Conclude your understanding of lymphoma with an in-depth look at its signs and symptoms, from common indicators to subtle clues.

Speaker : Dr Suvir Singh

Optimizing Treatment Options in Advanced Urothelial Carcinoma

Explore Dr. TamoJit Chaudhury’s expert insights on optimizing advanced urothelial carcinoma treatment, covering immunotherapy, targeted therapy, and clinical trial breakthroughs.

Speakers : Dr. Tamojit Chaudhury

Updates on the First Line Management of ALK+ NSCLC

In this webinar, a detailed discussion is done on Enhancing Outcomes in Advanced Lung Cancer

Speakers : Prof. Tony Mok

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

Join Prof. Jessica Lin as she explores key strategies for managing ALK+ NSCLC while prioritizing long-term patient safety

Speakers : Prof. Jessica Lin

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

Join Prof. Solange Peters as she explores post-progression strategies after first-line third-generation ALK inhibitors in NSCLC.

Speakers : Prof. Solange Peters

Oropharyngeal Cancer in Relation to HPV Status

Learn about the occurrence of oropharyngeal cancer in HPV negative patients through different case presentations.

Speakers : Dr. Ashish M Kaushal

Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Dr. Rohit R Pai compares Nimotuzumab plus chemoradiotherapy vs. placebo plus chemoradiotherapy in locally advanced nasopharyngeal carcinoma (LA-NPC).

Speakers : Dr. Rohit R Pai - Speaker

Role of Nimotuzumab in Management of Nasopharyngeal Cancer

Explore the role of Nimotuzumab in Nasopharyngeal Cancer management with Dr. Abhishek Raj, focusing on targeted therapy and improved patient outcomes.

Speakers : Dr. Abhishek Raj

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

Explore the benefits of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer with Dr. Shailesh Bondarde.

Speakers : Dr Shailesh Bondarde

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

Discover how CDK4/6 inhibitors extend progression-free survival (PFS) and overall survival (OS) in HR+/HER2- metastatic breast cancer (mBC) patients.

Speakers : Dr Parveen Jain

First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials

Explore expert insights on first-line maintenance therapy for metastatic urothelial carcinoma in this panel discussion featuring Dr. Tushar Patil, Dr. Varun Nagori, and Dr. Amol Dongre.

Speakers : Dr Tushar Patil ,Dr Varun Nagori ,Dr Amol Dongre


Recommended News For You

According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.

FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma

Smart exercise planning could boost recovery for people with cancer

Alternative Medicine for Breast Cancer: Study Raises Concern

Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit

Patients with head and neck cancer who cannot receive cisplatin now have new hope.

Recommended Articles For You

Clinical Methods in Hematology and Quality Improvement 

Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection 

Gene Therapy for Hemophilia: A New Hope on the Horizon 

Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes 
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Inner Thoughts of Leonard Bernstein, the "Maestro".

2.

Mobile prostate cancer screening clinic can ID the disease in disadvantaged men

3.

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC

4.

Parents, teachers at Missouri school want answers after string of cancer diagnoses

5.

A promising medication could slow brain tumors in children.

1.

Future-Ready Cancer Screening: What Every Clinician Should Know in 2025

2.

Cancer Evolution and Therapeutic Resistance: Mechanisms, Clinical Insights, and Emerging Strategies

3.

Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances

4.

Partial Gland Ablation in Prostate Cancer: Oncologic Outcomes in Intermediate-Risk Cases

5.

Generative AI for Adaptive Oncology Trial Design

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

2.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

3.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC

4.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

5.

Current Scenario of Cancer- The Incidence of Cancer in Men

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot